<DOC>
	<DOCNO>NCT00662688</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Anticoagulants , dalteparin , may help prevent blood clot form patient treated chemotherapy . It yet know whether gemcitabine effective give alone together dalteparin and/or capecitabine treat patient pancreatic cancer . PURPOSE : This randomized phase III trial study whether dalteparin prevents blood clot patient pancreatic cancer receive treatment different combination gemcitabine capecitabine .</brief_summary>
	<brief_title>Chemotherapy With Without Dalteparin Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To demonstrate preventive anticoagulation dalteparin reduces number thromboembolic event . - To determine number thromboembolic event occur preventive anticoagulation . Secondary - To determine survival without thrombotic event . - To determine progression-free overall survival . - To determine time response tumor . - To assess tolerance regimen . OUTLINE : This multicenter study . Patients stratify accord participate center WHO performance status ( 0-1 v 2 ) . Patients randomize 1 4 treatment arm . - Arm A : Patients receive chemotherapy investigator 's discretion - Arm B Patients receive chemotherapy investigator 's discretion dalteparin In arm , treatment repeat absence disease progression unacceptable toxicity . Blood plasma sample obtain baseline periodically study . Blood examine biomarkers , resistance activate protein C , mutation ( Leiden V factor , mutation G20210A , factor II gene ) . Thrombin generation factor VIIa VIII assess plasma . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas Metastatic disease Not amenable treatment No localize locally advanced disease Measurable disease ( metastatic primary tumor ) define ≥ 2 cm CT scan ≥ 1 cm spiral CT scan MRI No progressive thromboembolic disease No adenocarcinoma biliary tract ampulla Vater No known CNS metastases PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy &gt; 12 week ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Alkaline phosphatase &lt; 5 time normal Bilirubin &lt; 1.5 time normal Creatinine &lt; 1.5 time normal Creatinine clearance &lt; 30 mL/min Pain control stabilize via analgesic therapy Affiliation social security system Not pregnant nursing No control uncontrolled jaundice No contraindication study drug No cardiovascular accident ( myocardial infarction , cerebral vascular accident ) within past 6 month No serious cardiac and/or respiratory disease No cancer past 5 year except follow cancer , provide completely resect : Skin cancer Localized melanoma Carcinoma situ cervix No history thrombophilia No history heparininduced thrombocytopenia No uncontrolled persistent hypercalcemia No psychological , familial , social , and/or geographical condition precludes participation study PRIOR CONCURRENT THERAPY : No prior hematologic therapy metastatic disease No prior abdominal radiotherapy No concurrent corticosteroid antiemetic therapy No concurrent anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>thromboembolism</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
</DOC>